Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have relapsed/refractory (R/R) acute myeloid leukemia (AML). This study retrospectively analyzed the outcomes of...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Jonathan Feld, Douglas Tremblay, Mikaela Dougherty, Tina Czaplinska, Gillian Sanchez, Claudia Brady, Marina Kremyanskaya, Michal Bar-Natan, Alla Keyzner, Bridget K. Marcellino, Janice Gabrilove, Shyamala C. Navada, Lewis R. Silverman, Siraj M. El Jamal, John Mascarenhas, Alan H. Shih
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Wiley 2021-04-01
Seri Bilgileri:	HemaSphere
Online Erişim:	http://journals.lww.com/10.1097/HS9.0000000000000549
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Benzer Materyaller